Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Dangerous Good in said quantity, not available for sale.
- Synonyms
- 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide
- Correlated keywords
- mTORC MCF7 EGFPLC3 Hep-G2 COVID19 SARSCoV2 SARS-CoV2 SARSCoV MERSCoV DU-145 Salicylanilide BAY2353 BAY Bayer 2353 Bayluscid Cestocid Cestocide Devermin Devermine Fedal-Telmin Fenasal HL 2447 HL2447 Helmiantin Iomesan Lintex Mansonil Mato NSC178296 Nasemo Niclocide Niclosamide Phenasal Radeverm Ruby Sagimid Sulqui Tredemine Utosamide Vermitid Vermitin WR 46234 WR46234 Yomesan Zestocarp
- Product Overview:
Niclosamide is an anthelmintic that disrupts mitochondrial metabolism in parasitic worms and animal models.{29804,17472,27785} It inhibits STAT3 transcriptional activity (IC50 = 0.25 ?M in a reporter assay) and stimulates autophagy by reversibly inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling in MCF-7 cells expressing EGFP-LC3.{17472,18706} It completely inhibits phosphorylation of ribosomal S6 kinases (S6K) when used at a concentration of 3 µM.{17472} Niclosamide (1 µM) induces mitochondrial uncoupling, decreasing cellular ATP concentrations and increasing the ratio of ADP to ATP in HepG2 cells, and activates AMP-activated protein kinase (AMPK) in NIH3T3 cells.{27785} It also increases lipid oxidation by 5-fold in HepG2 cells. Niclosamide (5 and 10 µM) inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome CoV (MERS-CoV).{57523} It prevents high-fat diet-induced hepatic steatosis and insulin resistance and improves glycemic control in db/db mice when administered at a dose of 125 mg/kg per day.{27785} Niclosamide also inhibits proliferation and colony formation of DU145 prostate cancer cells, which have constitutively active STAT3 (IC50s = 0.7 and 0.1 µM, respectively).{18706}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.